learn Alfatradiol
a synthetic estrogen used topically as an anti-androgen
Search
forLearn
5 / 801 resultslearn retinoic acid
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 1000+ resultsresearch Persistent chemotherapy-induced alopecia: updates in diagnosis and treatment persistent chemotherapy induced alopecia: an updated approach
Persistent chemotherapy-induced alopecia (PCIA) occurs when hair regrowth is absent or incomplete beyond 6 months after chemotherapy, with an incidence ranging from 0.9% to 43%. Drugs like busulfan and taxanes are commonly associated with PCIA, which is characterized by noninflammatory alopecia and reduced hair shaft thickness. Trichoscopic evaluation is vital for predicting hair regrowth outcomes, especially in patients on adjuvant antiestrogen therapy. Scalp cooling therapies can prevent hair loss without increasing metastatic risk, improving quality of life. Topical and low-dose oral minoxidil show promise in promoting hair regrowth, while spironolactone may also be beneficial, though not yet studied as monotherapy for PCIA. Standardizing treatment response measures with trichoscopic follow-up is crucial for managing PCIA effectively.
research Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients
Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.
research Pattern Alopecia during Hormonal Anticancer Therapy in Patients with Breast Cancer
Some breast cancer patients on hormonal therapy may develop male or female pattern hair loss, which can sometimes be improved with topical treatments.
research Contemporary medical therapy for polycystic ovary syndrome
New treatments for PCOS focus on insulin resistance and reducing testosterone levels, along with traditional hormone therapies.
research Androgen receptor: A promising therapeutic target in breast cancer
The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
Community Join
5 / 1000+ resultscommunity Attempting to assist people with gyno sides on finasteride
Finasteride can cause gynecomastia due to hormonal imbalances. Management includes consulting an endocrinologist and using aromatase inhibitors like anastrozole or supplements like DIM and zinc.
community Microneedling Isn’t Snake Oil — It’s Evidence-Based. Let’s Talk Studies, Not Fear.
Microneedling is supported by research as an effective adjuvant treatment for hair loss, especially when combined with Minoxidil or Finasteride, with minimal side effects if done properly. Concerns about long-term safety and potential risks like infection or fibrosis remain, but many users report positive results.
community Hair Loss Worsened After Switching From Arimidex to Raloxifene, Despite Dutasteride
Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.
community results: 15 months fin + 4.5 months estrogen monotherapy + 4.5 months min
The user has been using finasteride for 15 months, minoxidil for 4.5 months, and estrogen monotherapy for 4.5 months. Their current regimen includes finasteride, minoxidil, alfatradiol, and estradiol gel.
community Duasteride and breast tissue accumulation.
The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.